The 60th Annual Meeting of the European Association for the Study of Diabetes (EASD) will be held in Madrid, Spain, from September 9-13, 2024. The EASD Annual Meeting is Europe's largest diabetes conference and takes place in a different city in Europe each year. The EASD Annual Meeting will provide an opportunity for researchers and healthcare professionals to share ideas and learn about cutting-edge research and technology, groundbreaking research results, and major advances in diabetes research, treatment, and care¹. EASD 2024 will be held as a hybrid event, and the venue located at the IFEMA Convention Center - Feria de Madrid Pavilion in Madrid, Spain.

The official website of EASD announced the titles of the selected abstracts for this congress, and two clinical studies of Gan & Lee's once-weekly insulin GZR4 have been selected for the Oral Presentation and Short Oral Discussion:

1. Safety, tolerability, and pharmacodynamics properties of a novel once-weekly insulin GZR4 in healthy subjects

Session: OP 02 Which day of the week is your insulin day?

Presentation type: Oral Presentation

Session time: September 10, 2024, 10:30-11:30 CEST

Link to the abstract：

https://cattendee.abstractsonline.com/meeting/20620/session/158

2. Pharmacokinetic and pharmacodynamic properties of a novel once-weekly insulin analogue GZR4 in people with type 2 diabetes

Session：SO 067 Breaking away with tradition or how to give insulin differently

Presentation type: Short Oral Discussion

Session time: September 10, 2024, 12:30-13:30 CEST

Link to the abstract：

https://cattendee.abstractsonline.com/meeting/20620/session/279 

GZR4:

GZR4 injection is an ultra-long-acting once-weekly insulin preparations that is independently developed by Gan & Lee Pharmaceuticals. GZR4 is expected to have a smoother glucose-lowering effect and less day-to-day variability in blood glucose levels. GZR4 is administered once weekly by subcutaneous injection, which is expected to help diabetic patients overcome injection barriers, initiate insulin therapy earlier, optimize the long-term diabetes management and improve their quality of life. Results from preclinical studies have shown that GZR4 has a significantly higher affinity for human serum albumin (HSA) and a significantly lower affinity for the insulin receptor than insulin Icodec, another once-weekly insulin analog. Moreover, unlike insulin Icodec, GZR4 maintains its activity in activating the insulin receptor after binding to albumin. In the studies using animal models of diabetes, the glucose-lowering effect of GZR4 was observed to be 2-3 times greater than that of insulin Icodec². Currently, the global development of GZR4 has entered Phase II clinical phase.

EASD

The European Association for the Study of Diabetes (EASD) is a membership-based academic non-profit organization. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting is one of the largest diabetes-related conferences in the world. Each year, the scientific programme of the conference includes more than 1,200 talks and presentations on the latest results from basic and clinical science in diabetes research discussed by leading experts in the field.

The detailed scientific programme of EASD 2024 and the titles of the selected abstracts have been published on the official website, if you want to get more information, please visit the official website of EASD Annual Meeting 2024 https://www.easd.org

Forward-looking statements

Forward-looking statements are based on our expectations and assumptions as of the date of the statements. Actual results may differ materially from those expressed in these forward-looking statements due to a variety of factors, and we can give no assurance that such results will be achieved in the future. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

References:

1. EASD’s 60th Annual Meeting. https://www.easd.org/annual-meeting/easd-2024.html  

2. WANCAI XING, WEI CHEN, YINING ZHANG, JING GAO, ANSHUN HE, JUN ZHANG, YING DENG, FANGKAI XUE, YONGCHUN WANG, HAO FU, RUNYAO ZHANG, JINHUI HUANG, ZHONGRU GAN; 823-P: Molecular and Pharmacological Properties of GZR4, a Once-Weekly Insulin Analog. Diabetes 14 June 2024; 73 (Supplement_1): 823–P. https://doi.org/10.2337/db24-823-P 

About Gan & Lee

Gan & Lee Pharmaceuticals developed the first Chinese domestic insulin analog. Currently, Gan & Lee has six core insulin products, including five insulin analog varieties: long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). The company has two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In China's 2024 National Insulin-Specific Centralized Procurement, Gan & Lee Pharmaceuticals ranked second overall and first among domestic companies in terms of procurement demand for insulin analogs. The company is also making strides in international markets, with the disposable pen needle (GanleeFine^®) approved by the US Food and Drug Administration (FDA) in 2020 and received GMP inspection approval from the European Medicines Agency (EMA) in 2024. These achievements significantly boost Gan & Lee’s competitiveness in both international and domestic markets.

In the future, Gan & Lee will strive for comprehensive coverage in diabetes treatment. Moving forward with its mission to become a world-class pharmaceutical company, Gan & Lee will also actively develop new chemical entities and biological drugs, focusing on treatments for metabolic diseases, cardiovascular diseases, and other therapeutic areas.